Photo Gallery

Login

Search

News & Updation

  • WJPPS OCTOBER ISSUE PUBLISHED
  • OCTOBER 2017 Issue has been successfully launched on 1 October 2017

  • ICV
  • WJPPS Rank with Index Copernicus Value 52.51 due to high reputation at International Level

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.041 to 6.647 due to high quality Publication at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  

Abstract

LOW DENSITY LIPROPROTEIN CHOLESTEROL GOAL LEVELS IN CARDIOVASCULAR SECONDARY PREVENTION

Martín A. Urtasun, Gustavo H. Marin*, Cristian Dorati1, Eliseo Ferrari, Héctor O. Buschiazzo, Perla Mordujovich de Buschiazzo

ABSTRACT

The Scandinavian Simvastatin Survival Study showed that the reduction of low density lipoprotein (LDL) cholesterol levels diminished 30% all causes mortality in coronary heart disease (CHD) patients. Later trials with statins indicated a positive relationship between CHD secondary prevention and continuously lower LDL-C levels. The Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]), recommended drug treatment of CHD or CHD risk equivalents patients, with LDL-C above 130 mg/dl and optional treatment between 100 and 129 mg/dl, with a goal value  100 mg/dl. In 2004, the same Program recommended an LDL-C goal of  70 mg/dl when cardiovascular risk is very high. This review examines main published clinical trials (2001-2016) of statins efficacy on CV secondary prevention, specially with LDL-C levels lower than 100 mg/dl and discusses its implementation at the current medical practice.

Keywords: Lipoproteins, LDL cholesterol, Coronary disease, drug therapy, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More